Modelling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo Arms of schizophrenia clinical trials

Clinical Pharmacokinetics

Volumn 51, Issue 4, 2012, Pages 261-275

  Pilla Reddy, Venkatesh ^a   Kozielska, Magdalena ^a   Johnson, Martin ^a   Suleiman, Ahmed Abbas ^a   Vermeulen, An ^b   Liu, Jing ^c   De Greef, Rik ^d   Groothuis, Geny M M ^a   Danhof, Meindert ^e   Proost, Johannes H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d NV ORGANON   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Modelling; Pharmacokinetics; Pharmacology; Placebo response; Schizophrenia

Indexed keywords

ASENAPINE; JNJ 37822681; JNJ 37837822681; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARTMENT MODEL; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; GEOGRAPHIC DISTRIBUTION; HUMAN; MATHEMATICAL MODEL; NONLINEAR SYSTEM; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NONLINEAR DYNAMICS; PATIENT DROPOUTS; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84863241410     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11598460-000000000-00000     Document Type: Article

References (44)

1. Kinon BJ, Potts AJ, Watson SB. Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiatry 2011; 24 (2): 107-13
2. Mallinckrodt CH, Tamura RN, Tanaka Y. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res 2011; 45 (9): 1202-7
3. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drugplacebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 2010; 36 (3): 504-9
4. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008; 34 (2): 286-91
5. Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155 (3): 230-3
6. Gomeni R, Lavergne A, Merlo-Pich E. Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci 2009; 36 (1): 4-10
7. Gomeni R, Merlo-Pich E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 2007; 63 (5): 595-613
8. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res 2005; 79 (2-3): 231-8
9. Overall JE, Gorham DR. The Brief Psychiatric Rating-Scale. Psychol Rep 1962; 10 (3): 799-812
10. Welge JA, Keck Jr PE. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: A meta-regression. Psychopharmacology (Berl) 2003; 166 (1): 1-10
11. Bhattaram VA, Siddiqui O, Kapcala LP, et al. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009; 11 (3): 456-64
12. Ploeger BA, Holford NHG. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat 2009; 8 (3): 225-38
13. Pilla Reddy V, Kozielska M, Johnson M, et al. Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 2011; 50 (7): 429-50
14. Roderick L, Rubin BD. Statistical analysis with missing data. New York: John Wiley & Sons, 2002
15. Diggle P, Kenward MG. Informative drop-out in longitudinal data-analysis. J R Stat Soc Ser C Appl Stat 1994; 43 (1): 49-93
16. Hu C, Szapary PO, YeildingN, et al. Informative dropoutmodeling of longitudinal ordered categorical data and model validation: Application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 2011; 38 (2): 237-60
17. Frame B, Miller R, Hutmacher MM. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J Pharmacokinet Pharmacodyn 2009; 36 (6): 565-84
18. Friberg LE, de Greef R, Kerbusch T, et al. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009; 86 (1): 84-91
19. Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68 (5): 568-77
20. Goyal N. Integrated modeling of PANSS and dropout analysis in patients with acute schizophrenia [abstract no. PII-56]. Clin Pharmacol Ther 2009 Feb; 85 Suppl. 1: S54 [online]. Available from URL: Http://www.nature.com/clpt/journal/ v85/n1s/pdf/clpt2008285a.pdf [Accessed 2012 Feb 22]
21. Petersson KJ, Vermeulen AM, Friberg LE. Could prolactin levels be a more informative predictor for clinical effect of D2-receptor antagonists than drug concentrations in the treatment of schizophrenia? [abstract no. 1541]. 18th Annual Meeting, Population Approach Group in Europe; 2009 Jun 23-25; St Petersburg [online]. Available from URL: Http://www.page-meeting.org/default. asp?abstract=1541 [Accessed 2012 Feb 22]
22. Center for Drug Evaluation and Research, US Food and Drug Administration. Clinical pharmacology and biopharmaceutics review: Aripiprazole (Abilify™) oral solution 1mg/mL[NDA no. 21-713; online]. Available from URL: Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/021713s000-Abilify- Clin PharmR.pdf [Accessed 2012 Feb 22]
23. Ortega I, Perez-Ruixo JJ, Stuyckens K, et al. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: Meta-analysis of 3 randomized, controlled clinical trials. J Clin Pharmacol 2010; 50 (3): 293-310
24. Piotrovsky V. Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores [abstract no. 773]. 14th Annual Meeting, Population Approach Group in Europe; 2005 Jun 16-17; Pamplona [online]. Available from URL: Http://www.page-meeting. org/default.asp?abstract=773 [Accessed 2012 Feb 22]
25. Beal S, Sheiner LB, Boeckmann A, et al.NONMEMuser's guides (1989-2009). Ellicott City (MD): Icon Development Solutions, 2009
26. Laporte-Simitsidis S, Girard P, Mismetti P, et al. Inter-study variability in population pharmacokinetic meta-analysis: When and how to estimate it? J Pharm Sci 2000; 89 (2): 155-67
27. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic pharmacodynamic models: 1. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20 (5): 511-28
28. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4 (4): E27
29. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79 (3): 241-57
30. Gastonguay MR, French JL, Heitjan DF, et al. Missing data in model-based pharmacometric applications: Points to consider. J Clin Pharmacol 2010; 50 (9): 63S-74S
31. Hu C, Sale ME.A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30 (1): 83-103
32. Zhang LP, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: Best-case performance. J Pharmacokinet Pharmacodyn 2003; 30 (6): 387-404
33. Zhang LP, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data II: Robustness of methods. J Pharmacokinet Pharmacodyn 2003; 30 (6): 405-16
34. Efron B, Tibshirani RJ. An introduction to the bootstrap. 6th ed. New York: Chapman & Hall/CRC, 1997
35. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37 (6): 486-95
36. Parke J, Holford NHG, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59 (1): 19-29
37. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9 (4): 503-12
38. Shang EY, Gibbs MA, Landen JW, et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J Pharmacokinet Pharmacodyn 2009; 36 (1): 63-80
39. Post TM. Disease system analysis between complexity and over simplification [dissertation]. Leiden: University of Leiden, 2009 [online]. Available from URL: Http://www.tipharma.com/fileadmin/user-upload/Theses/PDF/ Teun-Post-D2-104.pdf [Accessed 2012 Feb 22]
40. Chen YF, Wang SJ, Khin NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 2010; 9 (3): 217-29
41. Mallinckrodt CH, Zhang L, Prucka WR, et al. Signal detection and placebo response in schizophrenia: Parallels with depression. Psychopharmacol Bull 2010; 43 (1): 53-72
42. Post TM, Freijer JI, DeJongh J, et al. Disease system analysis: Basic disease progression models in degenerative disease. Pharm Res 2005; 22 (7): 1038-49
43. de Winter W, DeJongh J, Post T, et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 2006; 33 (3): 313-43
44. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008; 48: 33-60